Skip to content

Efficacy and safety of Point-Matrix Technology (PMT) lenses in slowing myopia progression in children: a randomized controlled clinical trial

The effectiveness and safety of Aiyanxing Point-Matrix Myopia Management Technology lenses in slowing myopia progression in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092759
Enrollment
Unknown
Registered
2024-11-22
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopia

Interventions

Point-Matrix Technology (PMT) lenses group:Wearing Point-Matrix Technology (PMT) lenses
Single vision lens (SVL) group:Wearing SVL lenses

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 13 Years

Inclusion criteria

Inclusion criteria: 1. 8-13 years old 2. There is no restriction on gender 3. Myopia equivalent spherical power -1.00~-5.00D 4. Astigmatism<= -1.50D 5. Ansometropia<= 1.00D 6. The best corrected visual acuity of one eye is not less than 20/20 7. Strabismus does not exceed 20? 8. Have good cognition and be able to cooperate with the examination 9. Able to consent and participate in the follow-up study 10. Willing to participate in this study and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1. Restricted activity due to medical illness, medications, or emotional state 2. Patients with organic diseases of the eyes and other parts 3. Those with a history of eye surgery in the past 4. Those who are combined with other drugs that may affect vision 5. Those who have worn contact lenses in the past month 6. Those who have used other myopia prevention and control methods in the past year (such as other defocus lenses, progressive lenses, bifocals, bifocal prisms, orthokeratology lenses, defocus soft lenses, defocus RGP, atropine, etc.) 7. Participation in other investigators that may directly or indirectly affect clinical outcomes within the past month 8. Subjects who are unable to communicate or do not follow instructions 9. Other conditions that the investigator considers inappropriate to participate in clinical trials

Design outcomes

Primary

MeasureTime frame
Spherical equivalent;

Secondary

MeasureTime frame
axial length;choroidal thickness;intraocular pressure;accommodative facility;

Countries

China

Contacts

Public ContactQingqing Tan

Department of Ophthalmology, Affiliated Hospital of North Sichuan Medical College

qqtan@nsmc.edu.cn+86 138 9083 4742

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026